Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $7.32 for the day, down -3.43% from the previous closing price of $7.58. In other words, the price has decreased by -$3.43 from its previous closing price. On the day, 6.54 million shares were traded. RXRX stock price reached its highest trading level at $8.0399 during the session, while it also had its lowest trading level at $7.31.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 13 ’24 when Secora Michael bought 15,000 shares for $7.66 per share.
Gibson Christopher bought 20,000 shares of RXRX for $154,800 on Nov 13 ’24. On Nov 12 ’24, another insider, Borgeson Blake, who serves as the Director of the company, bought 11,447 shares for $7.64 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2098212096 and an Enterprise Value of 1762633856. For the stock, the TTM Price-to-Sale (P/S) ratio is 32.19 while its Price-to-Book (P/B) ratio in mrq is 3.99. Its current Enterprise Value per Revenue stands at 27.041 whereas that against EBITDA is -4.84.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.22. The 50-Day Moving Average of the stock is 10.27%, while the 200-Day Moving Average is calculated to be -13.07%.
Shares Statistics:
RXRX traded an average of 4.93M shares per day over the past three months and 6294020 shares per day over the past ten days. A total of 226.26M shares are outstanding, with a floating share count of 223.86M. Insiders hold about 21.90% of the company’s shares, while institutions hold 79.35% stake in the company. Shares short for RXRX as of 1730332800 were 62427631 with a Short Ratio of 12.67, compared to 1727654400 on 62578756. Therefore, it implies a Short% of Shares Outstanding of 62427631 and a Short% of Float of 24.560000000000002.
